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Umbilical cord bilirubin as a predictor of
neonatal jaundice: a retrospective cohort
study
Kelsey D. J. Jones1,2, S E. Grossman3, Dharshini Kumaranayakam3, Arati Rao1,3, Greg Fegan4
and Narendra Aladangady1,3*
Abstract
Background: Hyperbilirubinaemia is a major cause of neonatal morbidity. Early identification of those infants most
at risk might allow the development of targeted primary preventative therapy and follow-up. The objective of this
study was to assess whether arterial umbilical cord bilirubin (aUCB) level at delivery predicts the development of
neonatal jaundice in term deliveries.
Methods: Retrospective analysis of hospital biochemistry records identified term deliveries with recorded aUCB.
Infant medical records were reviewed to identify those who developed neonatal hyperbilirubinaemia (requiring
treatment according to UK NICE guidelines) with/without a positive direct antiglobulin test (DAT).
Results: Of 1411 term deliveries with a clearly recorded aUCB, 30 infants developed clinically-significant jaundice (2.7%)
, of whom 8 were DAT + ve (0.6%) mostly due to ABO incompatibility. aUCB strongly predicted the development of
DAT + ve jaundice (area under the ROC curve = 0.996), as well as all-cause jaundice (area under the ROC curve = 0.74).
However, this effect was critically dependent on maternal blood group. Amongst infants at risk of ABO incompatibility
(maternal blood groups O + ve/O-ve, 39.7%) the predictive value of aUCB for all cause jaundice was strengthened (area
under the ROC curve = 0.88). Amongst those not at risk (defined maternal blood group not O + ve/O-ve, 51.0%) it
disappeared completely (area under the ROC curve = 0.46). A cutoff of 35 μmol/l for mothers with blood group
O + ve/O-ve increased the pre-test probability for all-cause jaundice of 4% to a post-test probability of 30%.
Conclusions: For infants of mothers with blood group O, aUCB predicts development of neonatal jaundice. There was
no evident utility for infants of mothers with other blood groups. Estimation of aUCB should be considered as a
strategy for early identification of those at risk of neonatal haemolytic jaundice.
Keywords: Neonatology, Jaundice, Haematology
Background
Hyperbilirubinaemia is one of the commonest causes of
admission to hospital in the neonatal period amongst term
babies in all settings [1–3]. Prevention of serious compli-
cations depends on effective early treatment, but clinically
significant jaundice may not develop until one or more
days after delivery. Current practice, which usually pro-
motes early discharge after delivery, may introduce delays
in recognition and initiation of medical therapy [4, 5].
Identification of biomarkers that could be measured
within a few hours following birth, which robustly predict
incident jaundice, would represent a significant advance.
Estimation of umbilical cord blood bilirubin (UCB) at
delivery is practicable, cheap and non-invasive. It could be
easily integrated with the current trend towards routine
umbilical cord blood biochemical evaluation practiced in
many centres. Several previous studies have investigated
the potential utility of UCB estimation in predicting sub-
sequent hyperbilirubinaemia [6–12]. Results have been in-
consistent, and a review by the UK National Institute for
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Health and Care Excellence (NICE) concluded that it was
not a useful index of risk [13].
In this study we exploited the fact that at our institu-
tion UCB estimation is routine, and performed a retro-
spective analysis to assess the potential utility of arterial
umbilical cord bilirubin (aUCB) in predicting clinically
significant hyperbilirubinaemia, and hyperbilirubinaemia
due to neonatal haemolytic disease.
Methods
Homerton University Hospital is an inner-London District
General Hospital providing maternity care to one of the
most economically deprived areas in the UK. The local
population is ethnically diverse, with large Afro-Caribbean,
Turkish, and Orthodox Jewish communities. The obstetric
unit is a local referral centre with approximately 5000 deliv-
eries annually, 9% of which are below 2.5 kg. The delivery
unit combines midwife and obstetric-led care, and is
equipped with a GEM4000 whole blood analyzer, which is
operated by delivery suite staff and used for umbilical cord
gas analysis at delivery. For this project we have exploited
the fact that it is departmental policy to perform umbilical
cord gas analysis on all obstetric-led deliveries, and that the
GEM4000 automatically provides total bilirubin estimation
on such samples.
From an electronic database backup of the delivery
unit whole blood analyzer, we extracted data on all sam-
ples processed in the 9 months from February to No-
vember 2010. We used the hospital case number and
date of birth to identify and group all samples belonging
to a single individual (mother), and used these data to
interrogate the electronic patient records of each mother
and infant pair.
Because it is well recognised that paired umbilical cord
blood samples are frequently mislabelled, we only con-
sidered samples to be a true arterial cord blood sample
if there was another sample with the same hospital case
number processed within 30 min, with a pH that was
higher by >0.02. This accounts for the fact that umbilical
cord veins are easier to sample than arteries such that
where a single or two identical samples are received they
are most likely to be venous regardless of how they have
been labelled [14].
We recorded clinical and demographic factors including
maternal blood group (in the UK all pregnant women are
offered prenatal blood group analysis to assess for risk of
Rhesus-incompatibility disease), gestation at delivery
(estimated by dating ultrasound scan or last menstrual
period), the infant’s sex and birthweight. We recorded ma-
ternal ethnicity because of ethnically-defined differences
in some causes of neonatal jaundice (e.g. glucose-6-
phosphate dehydrogenase deficiency (G6PD)). Electronic
notes and blood test results from the delivery admission
and any subsequent readmissions were scanned by two
experienced paediatricians (KJ and AR, who were blinded
to the aUBC level) in order to identify all infants who de-
veloped clinically significant jaundice. This was defined as
a single total bilirubin result above the phototherapy treat-
ment threshold on charts from the UK’s NICE Guideline
on Neonatal Jaundice [13]. We scanned electronic neo-
natal notes and cross-checked with separate laboratory da-
tabases to record positive direct antiglobulin tests (DAT)
and low glucose-6-phosphate dehydrogenase levels for
each term infant with an arterial cord blood sample.
Single variable logistic regression (for continuous or or-
dinal variables) or chi-squared (for categorical variables)
analyses were performed to screen for association with
clinically significant neonatal jaundice, and with DAT-
positive (haemolytic) neonatal jaundice. Variables demon-
strating significant associations (p < 0.05) were included in
a multivariable analysis. Receiver operator characteristic
(ROC) curves were plotted. Subgroup analyses was per-
formed amongst those mothers with either O-ve or
O + ve blood groups (whose infants are at risk of ABO in-
compatibility haemolytic disease), and mothers with a de-
fined blood group that was neither O-ve or O + ve (whose
infants are not at risk of ABO incompatibility). In our set-
ting ABO incompatibility is the commonest cause of
haemolytic jaundice. Analysis was performed in Stata ver-
sion 11.0.
The study was reviewed and approved by the UK
National Research Ethics Service (NRES) Committee
London – Harrow (reference 11/LO/0796) and received
institutional approval from Homerton University Hospi-
tals Research and Development Department.
Results
Over the 9-month period, there were 4069 inborn deliv-
eries, on whom umbilical cord blood analysis had been
performed on 2128 (52.2%). Of these, 263 (12.3%) were
premature (gestation less than 37 weeks) and 432
(20.3%) did not have an umbilical cord blood result that
could clearly be identified as arterial. Medical notes were
missing in 22, which left 1411 (66.3%) mother-infant
pairs who were included in the analysis.
3.7% of mothers had O-ve blood group, and 36.0% were
O + ve (39.7% group O, overall). In terms of self-defined
ethnicity, 27.3% of mothers were black (African or Carib-
bean origin), 7.3% were south Asian, and 6.3% were Mid-
dle Eastern. Median birthweight was 3390 g (interquartile
range (IQR) 3080 to 3680 g), and median gestation in
weeks + days was 40 + 0 (IQR 39 + 0 to 41 + 0, range
37 + 0 to 43 + 0). 52.4% of deliveries were male.
There were 30 episodes of clinically significant jaundice
(2.1%). 9 infants were found to be DAT + ve (0.6%) of
whom 8 were jaundiced, and there was a single case of
G6PD deficiency. One case of DAT + ve jaundice was due
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to Rhesus incompatibility (O-ve mother), and the rest
were due to ABO incompatibility (O + ve mothers).
Gestation and aUCB were both significantly associated
with development of clinically significant jaundice
(P = 0.001 and P < 0.001, respectively). Maternal blood
group was only significant when dichotomised into those
potentially at risk of ABO incompatibility (blood groups
O + ve or O-ve) or not (other blood groups) (P = 0.02).
Apart from blood group, the only variable associated
with DAT + ve jaundice was aUCB (P < 0.001), as shown
in Fig. 1.
ROC curves demonstrate that amongst all infants, aUCB
strongly predicts the development of DAT + ve jaundice
(area under the ROC curve = 0.996 (95% CI 0.991 to
0.998); Fig. 2a), as well as all-cause jaundice (area under the
ROC curve = 0.75 (95% CI 0.72 to 0.77); Fig. 2a) even when
DAT + ve cases are omitted (area under ROC curve = 0.68
(95% CI 0.66 to 0.71); graph not shown).
We separated out infants at risk of ABO incompatibil-
ity (i.e. whose mothers were blood groups O + ve or O-
ve) from those certainly not (with a recorded blood type
not O + ve or O-ve) and considered the groups separ-
ately. Amongst 560 (39.7%) infants at risk of ABO in-
compatibility, aUCB had similar specificity but
substantially higher sensitivity for predicting all-cause
jaundice than when all infants were considered, with an
area under the ROC curve of 0.89 (95% CI 0.86 to 0.91).
The area under the ROC curve for DAT + ve jaundice in
this group was 0.994 (0.982 to 0.998). Interestingly, the
predictive effect was completely lost for those not at risk
of ABO incompatibility (720 infants, 51.0%), with an
area under the ROC curve of 0.46 (95% CI 0.43 to 0.50;
Fig. 2b). Furthermore, considering only those at risk of
ABO incompatibility the effect of gestation on risk of
all-cause jaundice was no longer significant (P = 0.06).
The aUCB cutoff levels and sensitivity and specificity
for predicting all-cause and DAT + ve jaundice are pre-
sented in Tables 1 and 2. Furthermore, since the rate of
clinically significant jaundice, at 2.1% (3.9% in O + ve/
−ve mothers), was similar to that found in other studies
in similar settings, we also calculated positive and nega-
tive predictive values at the different cutoffs [15–17].
Finally, since all subjects in the study had verifiable ar-
terial and venous samples, we assessed the correlation
between arterial and venous bilurubin levels. The correl-
ation coefficient was 0.80 (P < 0.001).
Discussion
This study demonstrates that aUCB is potentially useful
screening tool for haemolytic jaundice in term infants of
mothers with blood groups O + ve or O-ve. Although
the study design has several limitations, it is the largest
study to date investigating the role of umbilical cord bili-
rubin in predicting neonatal jaundice in term babies,
and identifies a subgroup of infants in whom aUCB
screening may have considerable utility. Infants with
high aUCB could be subjected to primary preventative
measures such as early feeding, prophylactic photother-
apy, and enhanced monitoring, with the aim of prevent-
ing severe jaundice.
Consideration of umbilical cord bilirubin as an index of
risk for neonatal jaundice is not a new idea. It has been an
area of interest since the 1950s, and most studies have
found it to be a useful predictor to a greater or lesser ex-
tent [6]. Comparison and meta-analysis of studies has
been complicated by the fact the most have tended to con-
sider aUCB as a categorical instead of continuous variable.
Substantial differences in reported sensitivity and specifi-
city values may simply have reflected the use of different
arbitrary cutoffs. For example, Knupfer et al. found that
Fig. 1 a shows aUCB levels amongst all infants, infants with all-cause jaundice (P < 0.001), and infants with DAT + ve jaundice (P < 0.001). b
shows gestation amongst all infants, infants with all-cause jaundice (P = 0.02), and infants with DAT + ve jaundice (P = 0.28)
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using a cutoff of 30μmol/l to predict neonatal hyperbiliru-
binaemia had very high sensitivity and low specificity of
97% and 41.4% respectively (compared to 88.2% and
55.3% for that cutoff in our study), whereas Carbonell
et al. found that an aUCB cutoff of 37μmol/l had low
sensitivity but high specificity of 22.2% and of 94.7%,
(compared to 44.7% and 95.6% in our study) [8, 10].
Both studies have results not dissimilar to those
found in our analysis, even though their reported
conclusions appear to be contradictory. In addition,
direct comparison between studies may be misleading as
most do not make clear whether arterial, venous or a mix-
ture of umbilical samples were analysed. Our data suggest
that venous and arterial values are strongly correlated, but
that venous levels are consistently lower than arterial,
leaving open the possibility of systematic error when com-
paring between study groups.
A significant advantage of the current study is that in-
fants at risk of the most common cause of haemolytic dis-
ease of the newborn in our setting (ABO incompatibility)
have been considered separately to those not at risk, and
that the number of events in both arms is sufficient to
meaningfully compare the two. The data strongly suggest
that aUCB should be considered a predictor of jaundice
due to haemolytic disease rather than all-cause jaundice,
and that umbilical cord bilirubin estimation has no
predictive value for jaundice in infants not at risk of
haemolysis. This presents a further reason why compari-
son between studies is problematic, because it suggests
the predictive characteristics of aUCB will be partly deter-
mined by percentage of the population at risk of haemo-
lytic causes of jaundice, which is subject to geographic
variation. Although these results mainly reflect jaundice
due to ABO incompatibility, the two infants with haem-
olysis not caused by ABO also had very high aUCB; the
only infant with proven Rhesus-incompatibility disease
had the highest aUCB recorded in the study period at
113.9μmol/l, and the infant with G6PD manifesting as
early jaundice had an aUCB of 51μmol/l, on the 99th cen-
tile of our data.
The study has a number of limitations. Umbilical cord
blood specimens were not systematically processed dur-
ing the study period, with analysis undertaken in only
52% of inborn deliveries. Cord blood analysis was not
generally undertaken in deliveries under midwifery-led
care, introducing an important bias into our dataset to-
wards complicated pregnancies and deliveries requiring
medical intervention. Although these features might
Fig. 2 a shows ROC curves for aUCB predicting all cause jaundice (dashed line) or DAT + ve jaundice (thick line) amongst all infants. b shows
ROC curves for all-cause jaundice amongst infants at risk of ABO incompatibility (i.e. with maternal blood group O + ve or O-ve, thick line), and
amongst those infants not at risk (i.e. documented maternal blood group not O + ve or O-ve, dashed line). In both instances the symbols denote
aUCB cutoffs (in μmol/l) as follows: Diamond = 50, Triangle = 40, Circle = 30, Square = 20
Table 1 aUCB and all-cause jaundice
aUCB
(μmol/l)
All subjects Only O + ve/O-ve Mothers
Sens (%) Spec (%) PPV (%) NPV (%) LR+ LR- Sens (%) Spec (%) PPV (%) NPV (%) LR+ LR-
>20 68.4 59.2 4.4 98.6 1.7 0.53 90.9 56.1 7.8 99.3 2.1 0.16
>25 63.2 76.0 6.8 98.7 2.6 0.48 86.4 73.2 11.7 99.2 3.2 0.19
>30 55.3 88.2 11.5 98.6 4.7 0.51 77.3 86.4 18.9 98.9 5.7 0.26
>35 44.7 94.2 17.7 98.4 7.7 0.59 68.2 93.9 31.3 98.6 11.1 0.34
>40 36.8 97.7 30.4 98.2 15.8 0.65 59.1 97.4 48.1 98.3 22.7 0.42
>45 31.6 98.8 42.9 98.1 27.1 0.69 50.0 98.7 61.1 98.0 38.4 0.51
>50 23.7 99.5 56.3 97.9 46.5 0.77 36.4 99.3 66.7 97.4 48.9 0.64
Sens sensitivity, spec specificity, PPV positive predictive value, NPV negative predictive value, LR+ positive likelihood ratio, LR- negative likelihood ratio
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influence the probability of developing neonatal jaun-
dice, it was reassuring to see that the jaundice rate in
our sample was in line with previous population-
based studies. Furthermore the retrospective data cap-
ture is incomplete with substantial gaps, for example
maternal blood group is missing in 3.3% of cases. The
study presents data from a single centre that is atyp-
ical compared to the wider UK population, serving an
economically deprived and unusually ethnically di-
verse catchment area. Although our efforts to identify
infants with each of the three outcomes have been
thorough, it is difficult to exclude that some who did
develop jaundice have been miscategorised as not de-
veloping it, which could lead to overestimation of
sensitivity. It is disappointing that it was not possible
to identify an unambiguous arterial sample in such a
high proportion of cases. It may be that future studies
focus on venous levels, although occasional inadvert-
ent sampling of the artery will compromise specificity
in that case.
In our dataset small changes in aUCB cutoffs may be as-
sociated with substantial alterations in sensitivity and spe-
cificity for predicting hyperbilirubinaemia. The exact level
of an ‘ideal’ cutoff, will probably be different between dif-
ferent centres serving distinct populations. In our setting,
a cutoff of 35 μmol/l for mothers with blood group O + ve
or O-ve had a positive predictive value of almost a third
for predicting early neonatal jaundice, increasing the pre-
test probability of 4% to a post-test probability of 30%.
Conclusion
This study proves the concept that umbilical cord biliru-
bin is predictive of the development of neonatal jaun-
dice, especially haemolytic jaundice, in infants of O + ve
and O-ve mothers. It should prompt re-consideration of
the applicability of this practical, cheap and non-invasive
approach.
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Table 2 aUCB and DAT + ve jaundice
aUCB
(μmol/l)
All subjects Only O + ve/O-ve Mothers
Sens (%) Spec (%) PPV (%) NPV (%) LR+ LR- Sens (%) Spec (%) PPV (%) NPV (%) LR+ LR-
>20 100 58.8 1.4 100 2.4 0.00 100 55.1 3.1 100 2.2 0.00
>25 100 75.4 2.3 100 4.1 0.00 100 71.9 4.9 100 3.6 0.00
>30 100 87.5 4.4 100 8.0 0.00 100 85.1 8.9 100 6.7 0.00
>35 100 93.7 8.2 100 15.8 0.00 100 92.8 16.7 100 13.8 0.00
>40 100 97.3 17.4 100 36.9 0.00 100 96.6 29.6 100 29.1 0.00
>45 100 98.6 28.6 100 70.2 0.00 100 98.2 44.4 100 55.2 0.00
>50 62.5 99.2 31.3 99.8 79.7 0.38 62.5 98.7 41.7 99.5 49.3 0.30
Sens sensitivity, spec specificity, PPV positive predictive value, NPV negative predictive value, LR+ positive likelihood ratio, LR- negative likelihood ratio
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